Drugs / NL003
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01548378 | Mar 2012 → Jun 2014 | arterial occlusion, ischemic disease, peripheral vascular disease, ulcer disease | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05968118 | Jul 2022 → Jul 2023 | peripheral arterial disease | Beijing Northland Biotech. Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04274049 | Aug 2019 → Dec 2023 | arterial occlusion, ischemic disease, peripheral vascular disease, ulcer disease | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04275323 | Aug 2019 → Jun 2024 | arterial occlusion, limb ischemia, peripheral vascular disease, ulcer disease | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | AnGes, Inc. | Results 米国心臓学会発行のCirculationに正式に受理され公表されたHGF遺伝子治療用製品の論文の内容に関するお知らせ anges.co.jp ↗
潰瘍の 治癒までの期間 が短縮 する傾向が示唆された |
| 2025-11-05 | AnGes, Inc. | Results HGF遺伝子治療用製品の米国における第II相臨床試験結果の論文発表に関するお知らせ anges.co.jp ↗ |
| 2019-03-26 | AnGes, Inc. | Regulatory HGF遺伝子治療用製品の国内条件付承認を取得 国内初の遺伝子治療用製品、重症虚血肢を対象 anges.co.jp ↗ |
| 2019-02-21 | AnGes, Inc. | Regulatory 国内初の遺伝子治療用製品として HGF遺伝子治療薬の国内承認について anges.co.jp ↗ |
| 2018-01-22 | AnGes, Inc. | Regulatory HGF遺伝子治療薬の国内承認申請のお知らせ anges.co.jp ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-10 | AnGes, Inc. | 米国心臓学会発行のCirculationに正式に受理され公表されたHGF遺伝子治療用製品の論文の内容に関するお知らせ anges.co.jp ↗ |
| 2025-11-05 | AnGes, Inc. | HGF遺伝子治療用製品の米国における第II相臨床試験結果の論文発表に関するお知らせ anges.co.jp ↗ |
| 2019-03-26 | AnGes, Inc. | HGF遺伝子治療用製品の国内条件付承認を取得 国内初の遺伝子治療用製品、重症虚血肢を対象 anges.co.jp ↗ |
| 2019-02-21 | AnGes, Inc. | 国内初の遺伝子治療用製品として HGF遺伝子治療薬の国内承認について anges.co.jp ↗ |
| 2018-01-22 | AnGes, Inc. | HGF遺伝子治療薬の国内承認申請のお知らせ anges.co.jp ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NL003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04275323 ↗ |
| Action | Restore | “increasing the availability of HGF in ischemic tissues” NCT04275323 ↗ |
| Modality | Other / unclassified | “NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence” NCT01548378 ↗ |
| Route | Intramuscular | “intramuscular injections of NL003 into the calf” NCT01548378 ↗ |
| Target | HGF | “increasing the availability of HGF in ischemic tissues” NCT01548378 ↗ |